Glaxosmithkline Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2026 ,inter alia, to consider and approve Audited Financial Results (Standalone & Consolidated) for the year ended 31st March 2026 and dividend if any